Novo Nordisk stock after-hours at EUR 33.11: minus 0.57 percent versus Lang & Schwarz prior close
Published on 10/02/2026 at 18:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock was at EUR 33.11 in after-hours trading at 6:09 p.m. CEST on October 2, 2026, according to Lang & Schwarz. The price was down minus 0.57 percent versus the prior close of EUR 33.30.
After-hours trading
The Lang & Schwarz quote showed a bid of EUR 33.06 and an ask of EUR 33.16. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Novo Nordisk stock.
Wegovy liver-fat analysis
In a release dated October 1, 2026, Novo Nordisk A/S reported a post hoc analysis of 55 participants from the STEP UP trial program. Among 26 participants with liver fat above 5% at entry, 88.5%, or 23 people, reached levels below 5% by week 72. Mean liver fat in the semaglutide group declined from 8.8% at baseline to 3.1% at week 72.
HRS-1596 license agreement
In a September 29, 2026 release, Hengrui Pharma said it entered a license agreement with Novo Nordisk for HRS-1596, a phase I-ready GLP-1/GIP dual agonist designed for potential once-weekly oral dosing. Novo obtained exclusive development, manufacturing and commercialization rights outside mainland China, Hong Kong, Macao and Taiwan. The agreement has a potential value of up to USD 2.6 billion, including a USD 300 million upfront payment, and is expected to close in the fourth quarter of 2026 subject to customary conditions.
